How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
- 9 October 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 69 (15), 1498-1507
- https://doi.org/10.1212/01.wnl.0000271884.11129.f3
Abstract
Objective: Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset (R-onset) definite MS patients under “real-world” conditions.Keywords
This publication has 30 references indexed in Scilit:
- The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosisCurrent Medical Research and Opinion, 2005
- A comparison of health utility measures for the evaluation of multiple sclerosis treatmentsJournal of Neurology, Neurosurgery & Psychiatry, 2005
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Genetics of Multiple SclerosisSeminars in Neurology, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Multi-Attribute Preference FunctionsPharmacoEconomics, 1995
- Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-upBrain, 1993
- Rating neurologic impairment in multiple sclerosisNeurology, 1983